Immunosuppressives - TNF alpha inhibitors II.
Imunosupresiva - inhibitory TNF alfa II.
Czechia · Praha · how to bid here →
Your path to submission
- Deadline: 20 October at 14:00 — 17 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: CES, CES.
- Collect your evidence — the eligibility requirements are listed above; for many of them the analysis explains how to obtain them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every 2 months (521 awards, most recently September 2026) — the next award is due around November 2026 by that rhythm. The last award went to Takeda Pharmaceuticals Czech Republic s.r.o..n = 521
- 38% of this buyer's awards went to companies that had already won here before (1,211 awards since 2015, spread over 260 companies). That is well below the sector norm (69%) — this buyer switches suppliers more often than others.n = 1,211 awards since 2015
- The median procedure drew just one bid (1,005 procedures with a bid count); 56% ended with a single bidder. Sector: median 2 bids.n = 1,005
- The award came in at a median 94% of the estimated value (296 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 93%.n = 296
- 6% of the bids received came from other countries (506 procedures with a bid mix) — all bidders, not just the winners. Sector: 1%.n = 506
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 02/10/2026.
Foreign bidders
In Czechia · Medical equipment & pharma, 101 contracts went to foreign companies over the last 3 years (of 16,917 recorded awards) — mostly from Germany, Poland, Austria.
Submission language: CES.
Typical field: median 1 (from 433 awards).
What the buyer is looking for
The subject of the public contract is the supply of medicinal products for parenteral administration from the group of TNF alpha inhibitors (infliximab) for the treatment of patients in approved indications according to the SmPC valid on the date of submission of the tender. The subject of the public contract is the supply of medicinal products for parenteral administration from the group of TNF alpha inhibitors (adalimumab) for the treatment of patients in approved indications according to the SmPC valid on the date of submission of the tender.
Selection criteria — in the procurement documents
The buyer states in the notice that the selection criteria are in the procurement documents (link on the right), not in the EU form. The document analysis below extracts them from there — bid and evidence in Czech.
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| PHOENIX lékárenský velkoobchod, s.r.o. | 38 | 2022–2026 |
| Alliance Healthcare s.r.o. | 31 | 2015–2026 |
| PHARMOS, a.s. | 29 | 2022–2026 |
| PROMEDICA PRAHA GROUP, a.s. | 28 | 2022–2026 |
| CARDION s.r.o. | 17 | 2015–2026 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.